Details of the Target

General Information of Target

Target ID LDTP09913
Target Name CUGBP Elav-like family member 1 (CELF1)
Gene Name CELF1
Gene ID 10658
Synonyms
BRUNOL2; CUGBP; CUGBP1; NAB50; CUGBP Elav-like family member 1; CELF-1; 50 kDa nuclear polyadenylated RNA-binding protein; Bruno-like protein 2; CUG triplet repeat RNA-binding protein 1; CUG-BP1; CUG-BP- and ETR-3-like factor 1; Deadenylation factor CUG-BP; Embryo deadenylation element-binding protein homolog; EDEN-BP homolog; RNA-binding protein BRUNOL-2
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MSRIEKMSILGVRSFGIEDKDKQIITFFSPLTILVGPNGAGKTTIIECLKYICTGDFPPG
TKGNTFVHDPKVAQETDVRAQIRLQFRDVNGELIAVQRSMVCTQKSKKTEFKTLEGVITR
TKHGEKVSLSSKCAEIDREMISSLGVSKAVLNNVIFCHQEDSNWPLSEGKALKQKFDEIF
SATRYIKALETLRQVRQTQGQKVKEYQMELKYLKQYKEKACEIRDQITSKEAQLTSSKEI
VKSYENELDPLKNRLKEIEHNLSKIMKLDNEIKALDSRKKQMEKDNSELEEKMEKVFQGT
DEQLNDLYHNHQRTVREKERKLVDCHRELEKLNKESRLLNQEKSELLVEQGRLQLQADRH
QEHIRARDSLIQSLATQLELDGFERGPFSERQIKNFHKLVRERQEGEAKTANQLMNDFAE
KETLKQKQIDEIRDKKTGLGRIIELKSEILSKKQNELKNVKYELQQLEGSSDRILELDQE
LIKAERELSKAEKNSNVETLKMEVISLQNEKADLDRTLRKLDQEMEQLNHHTTTRTQMEM
LTKDKADKDEQIRKIKSRHSDELTSLLGYFPNKKQLEDWLHSKSKEINQTRDRLAKLNKE
LASSEQNKNHINNELKRKEEQLSSYEDKLFDVCGSQDFESDLDRLKEEIEKSSKQRAMLA
GATAVYSQFITQLTDENQSCCPVCQRVFQTEAELQEVISDLQSKLRLAPDKLKSTESELK
KKEKRRDEMLGLVPMRQSIIDLKEKEIPELRNKLQNVNRDIQRLKNDIEEQETLLGTIMP
EEESAKVCLTDVTIMERFQMELKDVERKIAQQAAKLQGIDLDRTVQQVNQEKQEKQHKLD
TVSSKIELNRKLIQDQQEQIQHLKSTTNELKSEKLQISTNLQRRQQLEEQTVELSTEVQS
LYREIKDAKEQVSPLETTLEKFQQEKEELINKKNTSNKIAQDKLNDIKEKVKNIHGYMKD
IENYIQDGKDDYKKQKETELNKVIAQLSECEKHKEKINEDMRLMRQDIDTQKIQERWLQD
NLTLRKRNEELKEVEEERKQHLKEMGQMQVLQMKSEHQKLEENIDNIKRNHNLALGRQKG
YEEEIIHFKKELREPQFRDAEEKYREMMIVMRTTELVNKDLDIYYKTLDQAIMKFHSMKM
EEINKIIRDLWRSTYRGQDIEYIEIRSDADENVSASDKRRNYNYRVVMLKGDTALDMRGR
CSAGQKVLASLIIRLALAETFCLNCGIIALDEPTTNLDRENIESLAHALVEIIKSRSQQR
NFQLLVITHDEDFVELLGRSEYVEKFYRIKKNIDQCSEIVKCSVSSLGFNVH
Target Bioclass
Other
Family
CELF/BRUNOL family
Subcellular location
Nucleus
Function
RNA-binding protein implicated in the regulation of several post-transcriptional events. Involved in pre-mRNA alternative splicing, mRNA translation and stability. Mediates exon inclusion and/or exclusion in pre-mRNA that are subject to tissue-specific and developmentally regulated alternative splicing. Specifically activates exon 5 inclusion of cardiac isoforms of TNNT2 during heart remodeling at the juvenile to adult transition. Acts both as an activator and as a repressor of a pair of coregulated exons: promotes inclusion of the smooth muscle (SM) exon but exclusion of the non-muscle (NM) exon in actinin pre-mRNAs. Activates SM exon 5 inclusion by antagonizing the repressive effect of PTB. Promotes exclusion of exon 11 of the INSR pre-mRNA. Inhibits, together with HNRNPH1, insulin receptor (IR) pre-mRNA exon 11 inclusion in myoblast. Increases translation and controls the choice of translation initiation codon of CEBPB mRNA. Increases mRNA translation of CEBPB in aging liver. Increases translation of CDKN1A mRNA by antagonizing the repressive effect of CALR3. Mediates rapid cytoplasmic mRNA deadenylation. Recruits the deadenylase PARN to the poly(A) tail of EDEN-containing mRNAs to promote their deadenylation. Required for completion of spermatogenesis. Binds to (CUG)n triplet repeats in the 3'-UTR of transcripts such as DMPK and to Bruno response elements (BREs). Binds to muscle-specific splicing enhancer (MSE) intronic sites flanking the alternative exon 5 of TNNT2 pre-mRNA. Binds to AU-rich sequences (AREs or EDEN-like) localized in the 3'-UTR of JUN and FOS mRNAs. Binds to the IR RNA. Binds to the 5'-region of CDKN1A and CEBPB mRNAs. Binds with the 5'-region of CEBPB mRNA in aging liver. May be a specific regulator of miRNA biogenesis. Binds to primary microRNA pri-MIR140 and, with CELF2, negatively regulates the processing to mature miRNA.
Uniprot ID
Q92879
Ensemble ID
ENST00000310513.10
HGNC ID
HGNC:2549

Probe(s) Labeling This Target

ABPP Probe
Click To Hide/Show 21 Probe Related to This Target
Probe name Structure Binding Site(Ratio) Interaction ID Ref
m-APA
 Probe Info  		12.45  LDD0402  [1]
STPyne
 Probe Info  		K109(7.40); K166(5.56); K184(8.33); K190(10.00)  LDD0277  [2]
BTD
 Probe Info  		C119(1.59); C177(1.58)  LDD1700  [3]
DBIA
 Probe Info  		C150(4.03)  LDD0204  [4]
5E-2FA
 Probe Info  		N.A.  LDD2235  [5]
ATP probe
 Probe Info  		N.A.  LDD0199  [6]
4-Iodoacetamidophenylacetylene
 Probe Info  		C177(0.00); C119(0.00); C150(0.00); C61(0.00)  LDD0038  [7]
IA-alkyne
 Probe Info  		C119(0.00); C177(0.00); C137(0.00)  LDD0032  [8]
Lodoacetamide azide
 Probe Info  		C177(0.00); C150(0.00); C137(0.00); C119(0.00)  LDD0037  [7]
ATP probe
 Probe Info  		N.A.  LDD0035  [9]
IPM
 Probe Info  		N.A.  LDD0025  [10]
JW-RF-010
 Probe Info  		N.A.  LDD0026  [10]
TFBX
 Probe Info  		C150(0.00); C119(0.00)  LDD0027  [10]
WYneO
 Probe Info  		N.A.  LDD0022  [11]
Phosphinate-6
 Probe Info  		N.A.  LDD0018  [12]
Acrolein
 Probe Info  		N.A.  LDD0217  [13]
Crotonaldehyde
 Probe Info  		C137(0.00); C177(0.00)  LDD0219  [13]
Methacrolein
 Probe Info  		C137(0.00); C177(0.00)  LDD0218  [13]
W1
 Probe Info  		N.A.  LDD0236  [14]
AOyne
 Probe Info  		7.40  LDD0443  [15]
NAIA_5
 Probe Info  		C177(0.00); C119(0.00); C150(0.00)  LDD2223  [16]
PAL-AfBPP Probe
Click To Hide/Show 3 Probe Related to This Target
Probe name Structure Binding Site(Ratio) Interaction ID Ref
FFF probe11
 Probe Info  		7.88  LDD0471  [17]
FFF probe14
 Probe Info  		18.09  LDD0477  [17]
FFF probe2
 Probe Info  		5.42  LDD0463  [17]

Competitor(s) Related to This Target

Competitor ID Name Cell line Binding Site(Ratio) Interaction ID Ref
 LDCM0548  1-(4-(Benzo[d][1,3]dioxol-5-ylmethyl)piperazin-1-yl)-2-nitroethan-1-one MDA-MB-231 C119(0.65); C177(0.96)  LDD2142  [3]
 LDCM0519  1-(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)-2-nitroethan-1-one MDA-MB-231 C119(0.73); C177(0.98); C150(0.79)  LDD2112  [3]
 LDCM0502  1-(Cyanoacetyl)piperidine MDA-MB-231 C119(0.73)  LDD2095  [3]
 LDCM0537  2-Cyano-N,N-dimethylacetamide MDA-MB-231 C119(0.94)  LDD2130  [3]
 LDCM0524  2-Cyano-N-(2-morpholin-4-yl-ethyl)-acetamide MDA-MB-231 C119(0.97); C177(0.89)  LDD2117  [3]
 LDCM0558  2-Cyano-N-phenylacetamide MDA-MB-231 C119(1.44); C177(1.28)  LDD2152  [3]
 LDCM0539  3-(4-Isopropylpiperazin-1-yl)-3-oxopropanenitrile MDA-MB-231 C119(0.65); C177(0.66)  LDD2132  [3]
 LDCM0538  4-(Cyanoacetyl)morpholine MDA-MB-231 C119(0.46)  LDD2131  [3]
 LDCM0026  4SU-RNA+native RNA HEK-293T C177(2.83)  LDD0372  [18]
 LDCM0545  Acetamide MDA-MB-231 C119(0.32)  LDD2138  [3]
 LDCM0520  AKOS000195272 MDA-MB-231 C119(0.69); C177(0.69)  LDD2113  [3]
 LDCM0156  Aniline NCI-H1299 12.23  LDD0403  [1]
 LDCM0102  BDHI 8 Jurkat C150(4.03)  LDD0204  [4]
 LDCM0498  BS-3668 MDA-MB-231 C119(0.63); C177(0.59)  LDD2091  [3]
 LDCM0108  Chloroacetamide HeLa C177(0.00); C137(0.00)  LDD0222  [13]
 LDCM0632  CL-Sc Hep-G2 C119(1.33)  LDD2227  [16]
 LDCM0625  F8 Ramos C119(1.36); 1.04; C150(0.88); C177(1.43)  LDD2187  [19]
 LDCM0572  Fragment10 Ramos C119(0.76); 0.26; C150(0.77); C177(0.77)  LDD2189  [19]
 LDCM0573  Fragment11 Ramos C119(0.20); 0.68; C150(0.01); C177(2.72)  LDD2190  [19]
 LDCM0574  Fragment12 Ramos C119(0.74); 0.88; C150(0.62); C177(0.85)  LDD2191  [19]
 LDCM0575  Fragment13 Ramos C119(1.06); 0.64; C150(0.79); C177(1.62)  LDD2192  [19]
 LDCM0576  Fragment14 Ramos C119(0.62); 0.73; C150(0.75); C177(0.27)  LDD2193  [19]
 LDCM0579  Fragment20 Ramos C119(0.64); 1.11; C150(0.57); C177(0.57)  LDD2194  [19]
 LDCM0580  Fragment21 Ramos C119(1.10); 0.42; C150(0.92); C177(1.32)  LDD2195  [19]
 LDCM0582  Fragment23 Ramos C119(0.71); 0.38; C150(1.18); C177(0.51)  LDD2196  [19]
 LDCM0578  Fragment27 Ramos C119(1.36); 0.65; C150(1.02); C177(1.53)  LDD2197  [19]
 LDCM0586  Fragment28 Ramos C119(0.73); 1.72; C150(1.57); C177(0.70)  LDD2198  [19]
 LDCM0588  Fragment30 Ramos C119(1.62); 0.32; C150(0.63); C177(2.01)  LDD2199  [19]
 LDCM0589  Fragment31 Ramos C119(0.92); 0.29; C150(1.04); C177(1.47)  LDD2200  [19]
 LDCM0590  Fragment32 Ramos C119(0.92); 0.34; C150(0.54); C177(0.88)  LDD2201  [19]
 LDCM0468  Fragment33 Ramos C119(1.13); 0.43; C150(0.67); C177(1.82)  LDD2202  [19]
 LDCM0596  Fragment38 Ramos C119(1.10); 0.46; C150(0.71); C177(0.94)  LDD2203  [19]
 LDCM0566  Fragment4 Ramos C119(0.67); 1.52; C150(0.89); C177(0.51)  LDD2184  [19]
 LDCM0610  Fragment52 Ramos C119(1.23); 0.39; C150(0.62); C177(1.96)  LDD2204  [19]
 LDCM0614  Fragment56 Ramos C119(1.72); 0.26; C150(0.74); C177(1.73)  LDD2205  [19]
 LDCM0569  Fragment7 Ramos C119(0.71); 1.10; C150(0.63); C177(0.35)  LDD2186  [19]
 LDCM0571  Fragment9 Ramos C119(0.58); 0.59; C150(0.77); C177(0.45)  LDD2188  [19]
 LDCM0107  IAA HeLa N.A.  LDD0221  [13]
 LDCM0022  KB02 Ramos C119(0.61); 1.30; C150(0.53); C177(0.34)  LDD2182  [19]
 LDCM0023  KB03 MDA-MB-231 C177(0.54)  LDD1701  [3]
 LDCM0024  KB05 G361 C203(1.25); C163(1.18)  LDD3311  [20]
 LDCM0509  N-(4-bromo-3,5-dimethylphenyl)-2-nitroacetamide MDA-MB-231 C119(1.05)  LDD2102  [3]
 LDCM0528  N-(4-bromophenyl)-2-cyano-N-phenylacetamide MDA-MB-231 C119(0.53); C177(0.64)  LDD2121  [3]
 LDCM0109  NEM HeLa N.A.  LDD0226  [13]
 LDCM0496  Nucleophilic fragment 11a MDA-MB-231 C119(0.63); C177(0.68)  LDD2089  [3]
 LDCM0499  Nucleophilic fragment 12b MDA-MB-231 C119(0.89); C177(1.19)  LDD2092  [3]
 LDCM0500  Nucleophilic fragment 13a MDA-MB-231 C119(0.84); C177(0.95)  LDD2093  [3]
 LDCM0501  Nucleophilic fragment 13b MDA-MB-231 C119(1.37); C177(2.25)  LDD2094  [3]
 LDCM0503  Nucleophilic fragment 14b MDA-MB-231 C119(0.78)  LDD2096  [3]
 LDCM0504  Nucleophilic fragment 15a MDA-MB-231 C119(0.75)  LDD2097  [3]
 LDCM0505  Nucleophilic fragment 15b MDA-MB-231 C119(0.91); C177(1.03)  LDD2098  [3]
 LDCM0506  Nucleophilic fragment 16a MDA-MB-231 C119(1.15); C177(0.95)  LDD2099  [3]
 LDCM0507  Nucleophilic fragment 16b MDA-MB-231 C119(0.85); C177(0.90); C150(0.45)  LDD2100  [3]
 LDCM0508  Nucleophilic fragment 17a MDA-MB-231 C119(0.55); C177(0.75)  LDD2101  [3]
 LDCM0511  Nucleophilic fragment 18b MDA-MB-231 C119(0.61); C177(0.93)  LDD2104  [3]
 LDCM0512  Nucleophilic fragment 19a MDA-MB-231 C119(1.15); C177(1.43)  LDD2105  [3]
 LDCM0514  Nucleophilic fragment 20a MDA-MB-231 C119(1.07); C177(0.91)  LDD2107  [3]
 LDCM0515  Nucleophilic fragment 20b MDA-MB-231 C119(0.71); C177(0.89)  LDD2108  [3]
 LDCM0516  Nucleophilic fragment 21a MDA-MB-231 C119(0.54); C177(1.01)  LDD2109  [3]
 LDCM0517  Nucleophilic fragment 21b MDA-MB-231 C119(1.12)  LDD2110  [3]
 LDCM0518  Nucleophilic fragment 22a MDA-MB-231 C119(1.04); C177(1.00)  LDD2111  [3]
 LDCM0521  Nucleophilic fragment 23b MDA-MB-231 C119(0.67); C177(0.96)  LDD2114  [3]
 LDCM0522  Nucleophilic fragment 24a MDA-MB-231 C119(0.45)  LDD2115  [3]
 LDCM0525  Nucleophilic fragment 25b MDA-MB-231 C119(0.76)  LDD2118  [3]
 LDCM0526  Nucleophilic fragment 26a MDA-MB-231 C119(1.61); C177(2.26)  LDD2119  [3]
 LDCM0529  Nucleophilic fragment 27b MDA-MB-231 C119(0.90)  LDD2122  [3]
 LDCM0530  Nucleophilic fragment 28a MDA-MB-231 C119(0.70); C177(1.08)  LDD2123  [3]
 LDCM0531  Nucleophilic fragment 28b MDA-MB-231 C119(0.90)  LDD2124  [3]
 LDCM0532  Nucleophilic fragment 29a MDA-MB-231 C177(1.01)  LDD2125  [3]
 LDCM0534  Nucleophilic fragment 30a MDA-MB-231 C119(1.07); C177(0.97)  LDD2127  [3]
 LDCM0536  Nucleophilic fragment 31 MDA-MB-231 C119(0.97); C177(0.92)  LDD2129  [3]
 LDCM0540  Nucleophilic fragment 35 MDA-MB-231 C119(0.47)  LDD2133  [3]
 LDCM0541  Nucleophilic fragment 36 MDA-MB-231 C119(0.45); C177(0.55)  LDD2134  [3]
 LDCM0542  Nucleophilic fragment 37 MDA-MB-231 C119(1.24); C177(1.10)  LDD2135  [3]
 LDCM0543  Nucleophilic fragment 38 MDA-MB-231 C119(0.99); C177(0.91)  LDD2136  [3]
 LDCM0544  Nucleophilic fragment 39 MDA-MB-231 C119(0.96)  LDD2137  [3]
 LDCM0211  Nucleophilic fragment 3b MDA-MB-231 C119(1.59); C177(1.58)  LDD1700  [3]
 LDCM0546  Nucleophilic fragment 40 MDA-MB-231 C119(0.74); C177(0.87)  LDD2140  [3]
 LDCM0547  Nucleophilic fragment 41 MDA-MB-231 C119(0.63); C177(0.57)  LDD2141  [3]
 LDCM0550  Nucleophilic fragment 5a MDA-MB-231 C119(2.06); C177(1.78)  LDD2144  [3]
 LDCM0551  Nucleophilic fragment 5b MDA-MB-231 C119(6.50)  LDD2145  [3]
 LDCM0552  Nucleophilic fragment 6a MDA-MB-231 C119(1.05); C177(0.96)  LDD2146  [3]
 LDCM0554  Nucleophilic fragment 7a MDA-MB-231 C119(0.43); C177(0.46)  LDD2148  [3]
 LDCM0556  Nucleophilic fragment 8a MDA-MB-231 C119(0.39); C177(0.57)  LDD2150  [3]
 LDCM0627  NUDT7-COV-1 HEK-293T C150(0.86)  LDD2206  [21]
 LDCM0628  OTUB2-COV-1 HEK-293T C150(0.71)  LDD2207  [21]

The Interaction Atlas With This Target

The Protein(s) Related To This Target

Other
Click To Hide/Show 1 Protein(s) Interacting with This Target
Protein name Family Uniprot ID
TAR DNA-binding protein 43 (TARDBP) . Q13148

References

1 Quantitative and Site-Specific Chemoproteomic Profiling of Targets of Acrolein. Chem Res Toxicol. 2019 Mar 18;32(3):467-473. doi: 10.1021/acs.chemrestox.8b00343. Epub 2019 Jan 15.
2 A Paal-Knorr agent for chemoproteomic profiling of targets of isoketals in cells. Chem Sci. 2021 Oct 15;12(43):14557-14563. doi: 10.1039/d1sc02230j. eCollection 2021 Nov 10.
Mass spectrometry data entry: PXD028270
3 Nucleophilic covalent ligand discovery for the cysteine redoxome. Nat Chem Biol. 2023 Nov;19(11):1309-1319. doi: 10.1038/s41589-023-01330-5. Epub 2023 May 29.
Mass spectrometry data entry: PXD039908 , PXD029761
4 Covalent Inhibition by a Natural Product-Inspired Latent Electrophile. J Am Chem Soc. 2023 May 24;145(20):11097-11109. doi: 10.1021/jacs.3c00598. Epub 2023 May 15.
5 Global profiling of functional histidines in live cells using small-molecule photosensitizer and chemical probe relay labelling. Nat Chem. 2024 Jun 4. doi: 10.1038/s41557-024-01545-6. Online ahead of print.
Mass spectrometry data entry: PXD042377
6 Targeted Proteomic Approaches for Proteome-Wide Characterizations of the AMP-Binding Capacities of Kinases. J Proteome Res. 2022 Aug 5;21(8):2063-2070. doi: 10.1021/acs.jproteome.2c00225. Epub 2022 Jul 12.
7 Enhancing Cysteine Chemoproteomic Coverage through Systematic Assessment of Click Chemistry Product Fragmentation. Anal Chem. 2022 Mar 8;94(9):3800-3810. doi: 10.1021/acs.analchem.1c04402. Epub 2022 Feb 23.
Mass spectrometry data entry: PXD028853
8 SP3-FAIMS Chemoproteomics for High-Coverage Profiling of the Human Cysteinome*. Chembiochem. 2021 May 14;22(10):1841-1851. doi: 10.1002/cbic.202000870. Epub 2021 Feb 18.
Mass spectrometry data entry: PXD023056 , PXD023059 , PXD023058 , PXD023057 , PXD023060
9 Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res. 2018 Jan 5;17(1):63-75. doi: 10.1021/acs.jproteome.7b00329. Epub 2017 Nov 22.
Mass spectrometry data entry: PXD006095 , PXD006096
10 Chemoproteomic Profiling by Cysteine Fluoroalkylation Reveals Myrocin G as an Inhibitor of the Nonhomologous End Joining DNA Repair Pathway. J Am Chem Soc. 2021 Dec 8;143(48):20332-20342. doi: 10.1021/jacs.1c09724. Epub 2021 Nov 24.
Mass spectrometry data entry: PXD029255
11 A modification-centric assessment tool for the performance of chemoproteomic probes. Nat Chem Biol. 2022 Aug;18(8):904-912. doi: 10.1038/s41589-022-01074-8. Epub 2022 Jul 21.
Mass spectrometry data entry: PXD027758 , PXD027755 , PXD027760 , PXD027762 , PXD027756 , PXD027591 , PXD007149 , PXD030064 , PXD032392 , PXD027789 , PXD027767 , PXD027764
12 DFT-Guided Discovery of Ethynyl-Triazolyl-Phosphinates as Modular Electrophiles for Chemoselective Cysteine Bioconjugation and Profiling. Angew Chem Int Ed Engl. 2022 Oct 10;61(41):e202205348. doi: 10.1002/anie.202205348. Epub 2022 Aug 22.
Mass spectrometry data entry: PXD033004
13 ACR-Based Probe for the Quantitative Profiling of Histidine Reactivity in the Human Proteome. J Am Chem Soc. 2023 Mar 8;145(9):5252-5260. doi: 10.1021/jacs.2c12653. Epub 2023 Feb 27.
14 Oxidant-Induced Bioconjugation for Protein Labeling in Live Cells. ACS Chem Biol. 2023 Jan 20;18(1):112-122. doi: 10.1021/acschembio.2c00740. Epub 2022 Dec 21.
15 Chemoproteomic profiling of targets of lipid-derived electrophiles by bioorthogonal aminooxy probe. Redox Biol. 2017 Aug;12:712-718. doi: 10.1016/j.redox.2017.04.001. Epub 2017 Apr 5.
16 N-Acryloylindole-alkyne (NAIA) enables imaging and profiling new ligandable cysteines and oxidized thiols by chemoproteomics. Nat Commun. 2023 Jun 15;14(1):3564. doi: 10.1038/s41467-023-39268-w.
Mass spectrometry data entry: PXD041264
17 Ligand and Target Discovery by Fragment-Based Screening in Human Cells. Cell. 2017 Jan 26;168(3):527-541.e29. doi: 10.1016/j.cell.2016.12.029. Epub 2017 Jan 19.
18 Chemoproteomic capture of RNA binding activity in living cells. Nat Commun. 2023 Oct 7;14(1):6282. doi: 10.1038/s41467-023-41844-z.
Mass spectrometry data entry: PXD044625
19 Site-specific quantitative cysteine profiling with data-independent acquisition-based mass spectrometry. Methods Enzymol. 2023;679:295-322. doi: 10.1016/bs.mie.2022.07.037. Epub 2022 Sep 7.
Mass spectrometry data entry: PXD027578
20 DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Cell. 2024 May 9;187(10):2536-2556.e30. doi: 10.1016/j.cell.2024.03.027. Epub 2024 Apr 22.
Mass spectrometry data entry: PXD047840
21 Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening. J Am Chem Soc. 2019 Jun 5;141(22):8951-8968. doi: 10.1021/jacs.9b02822. Epub 2019 May 22.